EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment

Luca Mastorino iD, Paolo Dapavo, Sara Susca, Caterina Cariti, Niccolò Siliquini, Anna Verrone, Elena Stroppiana, Michela Ortoncelli, Pietro Quaglino, Simone Ribero

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2024-01 · 22 (1) · 34-42

DOI: 10.1111/ddg.15251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 05.11.2023. Verfasst von Luca Mastorino und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Biological Products, Psoriasis, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologics targeting IL‐23 and IL‐17 show efficacy and safety in the treatment of moderate‐to‐severe psoriasis.

Objective

To investigate drug survival in patients with psoriasis treated with biologics. Patients and methods We performed a comparative evaluation of the achievement of PASI 90 and PASI ≤ 3 at 16, 28, and 52 weeks along with a DS (drug survival) analysis with IL‐17 and IL‐23 inhibitors brodalumab, ixekizumab, secukinumab, risankizumab, tildrakizumab, and guselkumab on 1,057 patients.

Results

IL‐17 inhibitors showed a faster achievement of PASI 90 and PASI ≤ 3 with significant superiority over IL‐23 inhibitors at week 16 (p < 0.001; 56% vs. 42% and 70% vs. 59%, respectively). A difference was shown in favor of IL‐23 inhibitors regarding DS (p < 0.001), which was 88% at 24 months vs. 75% for IL‐17 inhibitors. In multivariate analysis, IL‐23 inhibitors (HR 0.54 CI 0.37–0.78, p = 0.001), and male sex (HR 0.57 CI 0.42–0.76, p < 0.001) were all associated with a lower probability of drug interruption. Risankizumab (HR 0.42 CI 0.26‐0.69, p = 0.001), guselkumab (HR 0.49 CI 0.24–0.99, p = 0.046), and male sex (HR 0.57 CI 0.43–0.77, p < 0.001) were associated with a lower probability of drug interruption than secukinumab.

Conclusions

IL‐23 inhibitors showed the best performance on DS. Overall, the most effective class was IL‐17 inhibitors considering the short‐term effectiveness, but long‐term effectiveness is in favor of anti‐IL‐23.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsPsoriasisAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansMaleInterleukin-17Treatment OutcomeSeverity of Illness IndexInterleukin-23

Stichwörter der Autor:innen

IL-17 inhibitorsIL-23 inhibitorsPASIPsoriasisbiologicseffectivenessreal-life

Substanzen

secukinumabbrodalumabrisankizumabtildrakizumabixekizumabguselkumabInterleukin-17Biological ProductsInterleukin-23Antibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.

ORCID-Profile: Luca Mastorino

Zitieren

APA

Mastorino, L., Dapavo, P., Susca, S., Cariti, C., Siliquini, N., Verrone, A., Stroppiana, E., Ortoncelli, M., Quaglino, P., & Ribero, S. (2024). Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 22(1), 34-42. https://doi.org/10.1111/ddg.15251

Vancouver

Mastorino L, Dapavo P, Susca S, Cariti C, Siliquini N, Verrone A, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2024;22(1):34-42. doi:10.1111/ddg.15251

BibTeX
@article{Mastorino2024,
  author = {Mastorino, Luca and Dapavo, Paolo and Susca, Sara and Cariti, Caterina and Siliquini, Niccolò and Verrone, Anna and Stroppiana, Elena and Ortoncelli, Michela and Quaglino, Pietro and Ribero, Simone},
  title = {Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2024},
  volume = {22},
  number = {1},
  pages = {34--42},
  doi = {10.1111/ddg.15251}
}
Kostenlos starten →